Anti-payload Antibodies

Antibody-drug conjugates (ADCs) are a novel class of anticancer drugs that combine monoclonal antibodies with small molecule toxins, offering high target specificity and cytotoxicity. Following ADC administration, the payload can undergo payload release resulting in an increase in unbound payload and changes in ADC components (i.e., DAR distribution). Therefore, quantitative analysis of the conjugated antibody and payload on the antibody in vivo is crucial for assessing ADC efficacy, evaluating payload exposure at the target site, and determining the significance of DAR distribution and changes in average DAR value for providing overall assessment of ADC stability.

CUSABIO introduces specialized tools for preclinical and clinical stage antibody-drug research - anti-Payload antibodies. These antibodies can be utilized for plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug binding affinity, DAR value analysis, and evaluation of ADC drug efficacy.

For more detailed information, please refer to the webinar video replay.

Anti payload antibodies for ADC-Anti DXD

Figure. 1 DXD-the most promising payload for next-generation ADCs ^[1]

Supplemental Data

High purity verified by SEC-HPLC and SDS-PAGE with Anti-DXD antibody
(Code: CSB-MA996977I2m)

The Mouse Anti-DXD Antibody (Code: CSB-MA996977I2m) has a purity of more than 90% as determined by SEC-HPLC and SDS-PAGE.

High purity verified by SEC-HPLC and SDS-PAGE with Anti-Eribulin Antibody
(Code: CSB-MA943989I1m)

The Mouse Anti-DXD Antibody (Code: CSB-MA943989I1m) has a purity of more than 98% as determined by SEC-HPLC and SDS-PAGE.

The Binding Activity of Disitamab vedotin (Synonyms: RC48) with Anti-MMAE antibody
(Code: CSB-MA903890I1m)

Activity: Measured by its binding ability in a functional ELISA. Immobilized Disitamab vedotin (Synonyms: RC48) at 2 μg/mL can bind Anti-MMAE antibody, the EC₅₀ is 11.65 to 15.97 ng/mL.

The Binding Activity of T-DXd(DS-8201) with Anti-DXD antibody
(Code: CSB-MA996977I2m)

Activity: Measured by its binding ability in a functional ELISA. Immobilized T-DXd(DS-8201) at 2 μg/mL can bind Anti-DXD antibody, the activity was 4-5 times that of other companies.